Browse > Home / FDA News / Merck, AstraZeneca, Cornerstone Update Asthma Drug Warnings

Merck, AstraZeneca, Cornerstone Update Asthma Drug Warnings

August 31, 2009

Merck, AstraZeneca, Cornerstone Update Asthma Drug Warnings
Merck, AstraZeneca and Cornerstone Therapeutics regard added warnings about psychiatric effects to the labels of their leukotriene-modifier asthma drugs about brace months after the FDA requested the make some change in.. Neuropsychiatric events such as behavior and mood changes, including suicide and suicidal thinking and behavior, have been reported in some patients taking Merck’s Singulair (montelukast sodium), AstraZeneca’s Accolate (zafirlukast) and Cornerstone Therapeutics’ Zyflo and Zyflo CR (zileuton). The FDA asked the drugmakers to make different their labels in June to comprise warnings about in the same state events.

Written by Samanta · Filed Under FDA News